Compare · MDLN vs XAIR
MDLN vs XAIR
Side-by-side comparison of Medline Inc. (MDLN) and Beyond Air Inc. (XAIR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and XAIR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 22717.7x XAIR ($2.1M).
- Over the past year, MDLN is down 11.8% and XAIR is down 95.2% - MDLN leads by 83.5 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 6 for XAIR).
- MDLN has more recent analyst coverage (25 ratings vs 6 for XAIR).
- Company
- Medline Inc.
- Beyond Air Inc.
- Price
- $35.95-1.74%
- $2.24+7.18%
- Market cap
- $48.08B
- $2.1M
- 1M return
- +11.97%
- -27.74%
- 1Y return
- -11.77%
- -95.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 6
Beyond Air Inc.
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest XAIR
- SEC Form 4 filed by Beyond Air Inc.
- SEC Form 8-K filed by Beyond Air Inc.
- Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
- Large owner Lin Yi-Chien bought $56,590 worth of shares (20,393 units at $2.77), increasing direct ownership by 16% to 145,393 units (SEC Form 4)
- New insider Lin Yi-Chien claimed ownership of 125,000 shares (SEC Form 3)
- Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update
- Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
- Lake Street initiated coverage on Beyond Air with a new price target
- Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
- Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments